ArticleJournal of neuro-oncology2025
Comparison of the biological characteristics of glioblastoma tumorspheres obtained from fresh and cryopreserved glioblastoma tissues.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Brain tumor detection based on transcription regulation features identified from public cerebrospinal fluid cell-free DNA sequencing data.Translational cancer research · 2026Article
- Pharmacological transglutaminase 2 inhibition enhances temozolomide response in patient-derived glioblastoma tumorspheres.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeGlioblastoma (GBM) is the most common and aggressive primary brain tumor. Human GBM tumorspheres (TS) are essential for preclinical drug screening and establishing patient-derived xenograft (PDX) models, but their derivation is often limited to fresh tissue. Whether TS from cryopreserved tissues retain comparable molecular and biological properties to those from fresh tissues remains underexplored. We hypothesized that TS from cryopreserved tissues could provide a reliable alternative for TS derivation, thereby expanding accessibility for GBM research.
methodsTS isolation rates were compared across 39 primary GBM samples. Tumor tissues collected during surgical resection were divided into two groups: one processed immediately as fresh tissue, and the other cryopreserved for 1 month before processing. Gene expression profiling via RNA sequencing and biological comparisons, including cell proliferation, neuroglial differentiation, stemness, invasiveness, and responsiveness to radiation and temozolomide, were performed on three matched TS samples from each group. Tumorigenesis was also assessed using PDX models.
resultsTS were successfully isolated from 64.1% of fresh and 58.9% of cryopreserved tissues. Gene expression profiling revealed similar expression patterns in TS derived from both tissue types, despite variations in cancer subtypes. Cell proliferation, neuroglial differentiation, stemness, or invasiveness rates did not differ significantly between TS derived from fresh and cryopreserved tissues. All three GBM TS exhibited comparable responsiveness to temozolomide and radiation, as well as similar tumorigenic potential in the PDX models.
conclusionThese findings suggest an alternative method for isolating TS when immediate processing is not feasible, offering a time-independent approach for GBM research.
Indexed as
Identifiers
40325336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.